Items Tagged ‘monoclonal antibody’

October 25th, 2016

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status

By

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this week. Tecentriq is an agent that stimulates the immune system to recognize and mount an immune attack against cancer […]

View full entry

Tags: 2016, atezolizumab, BTD, ESMO, General Lung Cancer, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, PD-L1, Recurrent Lung Cancer - Non-Small Cell


November 17th, 2015

FDA Approves Darzalex Providing a New Treatment for Patients with Multiple Myeloma

By

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Darzalex appears to be effective in patients with multiple myeloma that has stopped responding to standard therapies according to study results recently published in the […]

View full entry

Tags: Darzlex, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


September 14th, 2015

Early Results of Opdivo® Combined with Yervoy® Presented at 16th World Conference on Lung Cancer

By

An early-stage study shows Opdivo® (nivolumab) treatment can be safely and effectively paired with relatively low and infrequent dosages of Yervoy® (ipilimumab) immunotherapy for patients with previously untreated lung cancer, researchers said on Monday at the 16th World Conference on Lung Cancer in Denver, CO. Lung cancer remains the leading cause of cancer-related deaths worldwide. […]

View full entry

Tags: clinical trial, CTLA4, Lung Cancer, Lung Cancer - Non-Small Cell, monoclonal antibody, News, nsclc, opdivo, PD-1 inhibitors, Recurrent Lung Cancer - Non-Small Cell, Yervoy


September 2nd, 2015

Immunotherapy Benefits Patients with Drug-Resistant Multiple Myeloma

By

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. The drug, daratumumab, proved generally safe in patients even […]

View full entry

Tags: antibody therapy, clinical trial, daratumumab, monoclonal antibody, Multiple Myeloma, News, Recurrent Multiple Myeloma


March 17th, 2015

XBiotech Launches Website and Call Center to Facilitate Recruitment for U.S. Phase III Study of Xilonix™ in Metastatic Colorectal Cancer

By

AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM  Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of […]

View full entry

Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite